SyncoZymes

What SyncoZymes does

SyncoZymes (Shanghai) Co., Ltd. is a privately held Chinese biotechnology company founded in 2007 and headquartered in the Shanghai Pudong Zhangjiang High-tech Park, operating as a subsidiary of SyncoZymes (Zhejiang) Co., Ltd. within a diversified biopharmaceutical group that also includes Zhejiang Hacon Pharmaceutical and Zhejiang Supor Pharmaceuticals. The company focuses on green process chemistry, with a technology platform built around biocatalysis and synthetic biology that underpins a proprietary enzyme library of 40+ series and more than 10,000 enzymes, plus an R&D team of over 50 scientists working in 2,000+ square meters of laboratory space. It has filed more than 160 patent applications and operates a 230-acre chemical drug industrialization base in Zhejiang with combined annual capacity of 1,200 tons of enzymes and co-enzymes, including 100 tons of NAD-series co-enzymes (NMN, NAD, NADP, NADH, NADPH).

The company's commercial offering is structured around three revenue streams: B2B raw material sales of enzymes, co-enzymes, pharmaceutical intermediates, and functional food raw materials to pharmaceutical and healthy-industry manufacturers; high-end CRO/CDMO services including testing and quality research for small-molecule drug development; and direct-to-consumer retail sales of branded NMN supplements under the SyncoZymes® label via Tmall Global, JD.com, and WeChat cross-border mini programs. It also manufactures the NMN ingredient for Longevity Life Sciences' CellVive brand, which is sold in Australia through Chemist Warehouse under TGA approval. SyncoZymes was the first manufacturer globally to obtain FDA NDI approval for NMN raw material (May 2022) and benefits from the FDA's December 2025 reinstatement of NMN as a legal dietary ingredient, alongside TGA approval in Australia (December 2024). Customer segments span pharmaceutical companies, dietary supplement and functional food manufacturers, and CRO/CDMO clients across China, the U.S., Australia, Singapore, and Hong Kong.

Name

SyncoZymes

Legal name

SyncoZymes (Shanghai) Co., Ltd.

Website

https://en.syncozymes.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

51–100 employees

Short description

SyncoZymes (Shanghai) Co., Ltd. is a Chinese biotechnology company specializing in green biocatalysis and synthetic biology for enzymes, NAD-series co-enzymes (including NMN), pharmaceutical intermediates, and functional food raw materials. It serves global pharmaceutical and dietary supplement manufacturers, CRO/CDMO clients, and direct-to-consumer retail channels.

Ownership category

akta.pro rank

Product category

Biocatalysis & Enzyme Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Miscellaneous Chemical Products (2890)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Enzyme manufacturing
• Biocatalysis technology
• Coenzyme production
• Pharmaceutical intermediates
• CRO CDMO services

Headquarters

HQ city

Zhoupu

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Raw Material Sales: SyncoZymes manufactures and sells enzyme raw materials, co-enzyme products (NMN, NAD series), pharmaceutical intermediates, and functional food raw materials to pharmaceutical and healthy industry customers worldwide.
2. CRO/CDMO Services: Provides high-end CRO (Contract Research Organization) and CDMO (Contract Development and Manufacturing Organization) services, including testing and quality research services for small molecule drug research and development.
3. Retail NMN Products: SyncoZymes owns retail NMN brand 'SyncoZymes®' sold directly to consumers through e-commerce platforms including Tmall Global, JD.com, and WeChat mini programs.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels1 record

Core offering

SyncoZymes develops and manufactures enzymes, co-enzymes (NAD series including NMN, NAD, NADP, NADH, NADPH), functional food raw materials, and pharmaceutical intermediates using proprietary green process chemistry and biocatalysis. The company also provides CRO/CDMO services and contract manufacturing for life-sciences partners, and operates a consumer retail brand (SyncoZymes®) for NMN supplements sold through Chinese e-commerce platforms.

Product overview

SyncoZymes is a biotechnology company offering a portfolio of enzyme and co-enzyme products along with contract manufacturing services. The core product lines include Enzymes (large enzyme library with 40 series and 10,000+ enzymes), Co-enzymes (NAD series including NMN, NAD, NADP, NADH, NADPH with 100 tons annual capacity), Functional Food Raw Materials, and Pharmaceutical Intermediates. These are supported by CRO/CDMO Services and Testing and Quality Research Services. The company also markets retail products under the SyncoZymes® brand (including NMN supplements) and manufactures CellVive NMN under license for Longevity Life Sciences.

Differentiator

Problem solved

Functional benefit

Brands

• CellVive NMN: NMN ingredient manufactured by SyncoZymes for Australian biotech company Longevity Life Sciences, approved by TGA for dietary supplements in Australia

Products and services

• Enzyme Catalog (40+ series, 10,000+ products) Broad industrial enzyme product line spanning 40+ enzyme series and 10,000+ individual products, manufactured via proprietary biocatalysis and green process chemistry, sold to pharmaceutical, nutraceutical, and life-sciences customers.
• NAD Series Co-enzymes (NMN, NAD, NADP, NADH, NADPH) Co-enzyme product line covering the NAD series including NMN (nicotinamide mononucleotide), NAD, NADP, NADH, and NADPH, manufactured using proprietary biosynthesis technology and supplied as raw materials to nutraceutical, pharmaceutical, and supplement manufacturers.
• Functional Food Raw Materials Functional food ingredient raw materials developed via synthetic biology and biocatalysis, supplied to functional food and dietary supplement manufacturers.
• Pharmaceutical Intermediates Pharmaceutical intermediates manufactured through green process chemistry and biotransformation, supplied to pharmaceutical companies for drug development and production.
• CellVive NMN (OEM for Longevity Life Sciences, Australia) NMN product manufactured by SyncoZymes on an OEM basis for Longevity Life Sciences in Australia, sold internationally under the CellVive brand.
• SyncoZymes® NMN Consumer Supplement Consumer-facing NMN dietary supplement sold under the SyncoZymes® retail brand via Tmall Global, JD.com, and WeChat, targeting health-conscious individual consumers seeking anti-aging and longevity products.
• CRO/CDMO Services Contract research, development, and manufacturing services for life-sciences partners, leveraging SyncoZymes' biocatalysis and green chemistry capabilities.
• Testing and Quality Research Services Analytical testing and quality research services supporting enzyme, co-enzyme, and biochemical product development and manufacturing for B2B customers.

Quantifiable outcome

• First company globally to receive FDA NDI certification for NMN raw material (May 2022)
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered minor and core.

• Inner Mongolia KingdomwayminorOthers · 1 December 2025Alongside SyncoZymes, Inner Mongolia Kingdomway received FDA confirmation letters in December 2025 that NMN can be legally marketed as a dietary supplement in the United States. Both companies were among the first manufacturers to receive NDI approval for NMN.
• Longevity Life SciencescoreStrategic or Co-development Partner · 1 December 2024SyncoZymes manufactures CellVive NMN for Australian biotech company Longevity Life Sciences. The TGA-approved NMN ingredient was sourced from this partnership, making Australia the first country globally to permit NMN in dietary supplements. Longevity Life Sciences plans to launch finished products in Australia, Singapore, and Hong Kong via e-commerce while conducting human clinical trials with the University of Sydney.
• University of SydneycoreStrategic or Co-development Partner · 1 December 2024Longevity Life Sciences is conducting human clinical trials in partnership with the University of Sydney for CellVive NMN products. SyncoZymes manufactures the NMN ingredient used in these clinical studies.
• Chemist WarehousecoreChannel Partner/ Reseller/ DistributorAustralia's leading pharmacy chain with nearly half the vitamin market share, Chemist Warehouse retails NMN supplements from Longevity Life Sciences (CellVive NMN manufactured by SyncoZymes) at AUD$39.99-59.99, significantly below overseas markets. Only CellVive NMN supplements are permitted for domestic sale under TGA regulations.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• ChromaDex: US-based NAD-precursor (Niagen/NR) ingredient supplier and finished-product company; competes with SyncoZymes' NMN/NAD-series co-enzyme business in the longevity supplement market.
• Asymchem: Leading Chinese CDMO for small-molecule APIs and intermediates with comparable GMP manufacturing scale; competes for the same pharmaceutical intermediates and CRO/CDMO contracts as SyncoZymes.
• Codexis: US-listed biocatalysis and enzyme engineering company providing enzyme platforms and CDMO services for small-molecule APIs; directly comparable to SyncoZymes' enzyme library and biotransformation CDMO offering.
• Amano Enzyme: Japanese specialty enzyme manufacturer with deep enzyme libraries serving pharmaceutical and food applications; comparable to SyncoZymes' enzyme catalogue and biocatalysis services.
• Zhejiang Medicine: Chinese vitamins and nutrition ingredients producer with NMN and co-enzyme exposure; competes with SyncoZymes in NAD-precursor raw materials and functional food ingredients.
• Inner Mongolia Kingdomway: Chinese NMN and vitamin manufacturer that co-received FDA confirmation letters with SyncoZymes in December 2025; competes directly in NMN raw material supply and CDMO intermediates.

Broad incumbents

• Novozymes (Novonesis): Global incumbent in industrial enzymes and biocatalysis with a much broader enzyme portfolio; comparable to SyncoZymes' enzyme library and biotransformation technology base, though not focused on NMN/co-enzyme CDMO.
• WuXi AppTec / WuXi STA: China's largest CRO/CDMO with deep small-molecule API and intermediate capabilities; a broad incumbent competing for the same pharmaceutical intermediate and CDMO customers as SyncoZymes.

Regional players

• AB Enzymes (Associated British Foods): European industrial enzyme manufacturer serving food and pharma applications; comparable to SyncoZymes' enzyme portfolio but primarily serving European rather than Asian markets.

Emerging players

• Metro International Biotech: US-based NMN-focused clinical-stage company; an emerging player in the NMN clinical and consumer space that intersects with SyncoZymes' raw material supply business.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/syncozymes-shanghai-co.ltd

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SyncoZymes